P. Darke

发表

HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins.

D. Veber, R. Freidinger, V. Garsky, 1988, Biochemical and biophysical research communications.

HIV protease as an inhibitor target for the treatment of AIDS.

P. Darke, J. Huff, Joel R. Huff, 1994, Advances in pharmacology.

Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.

L. Kuo, P. Darke, Z. Chen, 1996, The Journal of biological chemistry.

Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.

P. Darke, W. Schleif, J. Quintero, 1992, Journal of Medicinal Chemistry.

Fluorescent oligonucleotides and deoxynucleotide triphosphates: preparation and their interaction with the large (Klenow) fragment of Escherichia coli DNA polymerase I.

S. Benkovic, P. Darke, D. Allen, 1989, Biochemistry.

Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution.

R. Dixon, J. Springer, P. Darke, 1991, The Journal of biological chemistry.

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

M. Navia, J. Springer, P. Darke, 1989, Nature.

Structure and Function of the Hypertension Variant A486V of G Protein-coupled Receptor Kinase 4*

P. Darke, S. Munshi, D. Hall, 2015, The Journal of Biological Chemistry.

Structure of Human Prostasin, a Target for the Regulation of Hypertension*

H. Su, P. Darke, S. Munshi, 2008, Journal of Biological Chemistry.

Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.

S. Stirdivant, L. Kuo, P. Darke, 2005, Biochemistry.

Dimerization and Activation of the Herpes Simplex Virus Type 1 Protease*

P. Darke, U. Schmidt, Paul L. Darke, 1997, The Journal of Biological Chemistry.

Active Human Cytomegalovirus Protease Is a Dimer (*)

L. Kuo, P. Darke, D. Hall, 1996, The Journal of Biological Chemistry.

Activation of the Herpes Simplex Virus Type 1 Protease (*)

P. Darke, D. Hall, 1995, The Journal of Biological Chemistry.

Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.

D. Walters, P. Darke, W. Schleif, 1996, Journal of medicinal chemistry.

Nonpeptidal P2 Ligands for HIV Protease Inhibitors: Structure‐Based Design, Synthesis, and Biological Evaluation.

Arun K. Ghosh, D. Walters, P. Darke, 1996 .

The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.

P. Darke, M. Holloway, C. Culberson, 1994, Journal of medicinal chemistry.

Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands.

P. Darke, M. Holloway, A. Ghosh, 1993, Journal of medicinal chemistry.

48 – Comparison of the Dimerization, Stability and Inhibitor Binding Between HIV-1 Protease Wild Type and Active Site Mutant

R. Dixon, P. Darke, I. Sigal, 1990 .

Purification of active herpes simplex virus-1 protease expressed in Escherichia coli.

L. Kuo, P. Darke, E. Chen, 1994, The Journal of biological chemistry.

Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution.

L. Kuo, P. Darke, S. Munshi, 2003, Acta crystallographica. Section D, Biological crystallography.

Inhibition of Hepatitis C Virus NS2/3 Processing by NS4A Peptides

L. Kuo, P. Darke, L. Waxman, 1999, The Journal of Biological Chemistry.

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

P. Darke, W. Schleif, O. M. Blahy, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Stereoselective synthesis of the hydroxyethylene isostere of the HIV protease (Tyr-Pro) cleavage site

P. Darke, J. Thies, W. J. Thompson, 1992 .

Pyrrolinone-Based HIV Protease Inhibitors. Design, Synthesis, and Antiviral Activity: Evidence for Improved Transport

P. Darke, W. Schleif, E. Emini, 1995 .

The Herpesvirus Proteases as Targets for Antiviral Chemotherapy

P. Darke, L. Waxman, 2000, Antiviral chemistry & chemotherapy.

3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV Protease.

Arun K. Ghosh, P. Anderson, P. Darke, 1993, Journal of the American Chemical Society.

A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.

P. Darke, W. Schleif, T. Tucker, 1992, Journal of medicinal chemistry.

Synthesis and evaluation of pyridyl analogs of L-735,524: Potent HIV-1 protease inhibitors

P. Anderson, Jiunn H. Lin, P. Darke, 1994 .

L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.

P. Darke, W. Schleif, J. Quintero, 1994, Journal of medicinal chemistry.

Potent HIV-1 Protease Inhibitors: Stereoselective Synthesis of a Dipeptide Mimic.

Arun K. Ghosh, P. Darke, W. J. Thompson, 1993, The Journal of organic chemistry.

Cycloalkylpiperazines as HIV-1 protease inhibitors: enhanced oral absorption

B. E. Evans, P. Anderson, Jiunn H. Lin, 1995 .

Cobra venom phospholipase A2: A review of its action toward lipid/water interfaces

A. Plückthun, E. Dennis, P. Darke, 1981, Molecular and Cellular Biochemistry.

Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates.

L. Kuo, P. Darke, D. Hall, 1994, Biochemistry.

Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors

Christopher L. Daniels, D. Hazuda, Sujata Sharma, 2010, Journal of Virology.

Further characterization and N-terminal sequence of cobra venom phospholipase A2.

E. Dennis, P. Darke, R. Deems, 1980, Biochimica et biophysica acta.

Interaction of phospholipase A2 from cobra venom with Cibacron Blue F3GA.

E. Dennis, P. Darke, R. Deems, 1980, Biochemistry.

HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity.

P. Darke, A. Deana, S. Graham, 1992, Journal of medicinal chemistry.

L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor.

W. M. Sanders, P. Darke, I. Sigal, 1991, Journal of medicinal chemistry.

Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.

E A Emini, P. Anderson, P. Darke, 1991, Journal of medicinal chemistry.

HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.

W. M. Sanders, P. Anderson, P. Darke, 1993, Drug design and discovery.

Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.

E A Emini, L. Kuo, P. Darke, 2000, Journal of medicinal chemistry.

3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.

E A Emini, Arun K. Ghosh, P. Darke, 1993, Journal of medicinal chemistry.

Characterization of an active single polypeptide form of the human immunodeficiency virus type 1 protease.

R. Dixon, P. Darke, M. Holloway, 1990, The Journal of biological chemistry.

Crystal Structure of the Apo, Unactivated Insulin-like Growth Factor-1 Receptor Kinase

S. Stirdivant, L. Kuo, P. Darke, 2002, The Journal of Biological Chemistry.

Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met

P. Darke, S. Munshi, D. Hall, 2011, The Journal of Biological Chemistry.

Role of coenzyme in aminotransferase turnover.

F. Kenney, P. Darke, K. L. Lee, 1977, The Journal of biological chemistry.

Host cell factor requirement for hepatitis C virus enzyme maturation

L. Kuo, P. Darke, B. Pollok, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration.

L. Kuo, P. Darke, J. Zugay, 1992, The Journal of biological chemistry.

A general procedure for the purification of human beta-secretase expressed in Escherichia coli.

L. Kuo, P. Darke, S. Munshi, 2004, Protein expression and purification.

Novel conformationally constrained HIV-1 protease inhibitors: rational design, enzyme inhibition, and X-ray structure of an enzyme-inhibtor complex

P. Anderson, P. Darke, J. Huff, 1994 .

Conformationally constrained HIV-1 protease inhibitors

P. Anderson, P. Darke, J. Huff, 1994 .

24 – Human Immunodeficiency Virus (Type 1) Protease: Enzymology and Three-Dimensional Structure of a New AIDS Drug Target

P. Darke, C. Leu, I. Sigal, 1990 .

Affinity purification of the HIV-1 protease.

R. Dixon, V. Garsky, P. Darke, 1989, Biochemical and biophysical research communications.

Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease.

R. Dixon, P. Darke, C. Leu, 1989, The Journal of biological chemistry.

Elucidation of Basic Mechanistic and Kinetic Properties of Influenza Endonuclease Using Chemically Synthesized RNAs (*)

R. Dempski, L. Kuo, P. Darke, 1996, The Journal of Biological Chemistry.

Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus protease.

P. Darke, R. Nutt, S. Brady, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transport.

P. Darke, E. Emini, R. Hirschmann, 1994, Journal of medicinal chemistry.

Design and synthesis of HIV protease inhibitors. Variations of the carboxy terminus of the HIV protease inhibitor L-682,679.

W. M. Sanders, P. Darke, I. Sigal, 1991, Journal of medicinal chemistry.

Substituted alkylpyridines as P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors: Improved pharmacokinetic profiles

P. Anderson, P. Darke, W. Schleif, 1995 .

Thiophene derivatives as extremely high affinity P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors

P. Anderson, P. Darke, W. Schleif, 1995 .

A new hydroxyethylamine class of HIV-1 protease inhibitors with high antiviral potency and oral bioavailability

P. Anderson, P. Darke, W. Schleif, 1994 .

Stability of dimeric retroviral proteases.

P. Darke, 1994, Methods in enzymology.

Structure-activity studies and antiviral properties of hydroxyethylene transition state inhibitors of HIV-1 protease

P. Anderson, P. Darke, W. Schleif, 1992 .

Interaction of mutant forms of the HIV-1 protease with substrate and inhibitors.

R. Dixon, P. Darke, C. Leu, 1991, Advances in experimental medicine and biology.

Crystallization of the aspartylprotease from the human immunodeficiency virus, HIV-1.

M. Navia, J. Springer, P. Darke, 1989, The Journal of biological chemistry.

L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease. III. Biological activity.

P. Darke, K. Silverman, G. Bills, 1992, The Journal of antibiotics.

HIV-1 protease inhibitory activity of L-694,746, a novel metabolite of L-689,502.

P. Darke, G. Garrity, B. Arison, 1991, Biochemical and biophysical research communications.

A Collaborative Screening Program for the Discovery of Inhibitors of HCV NS2/3 cis-Cleaving Protease Activity

L. Kuo, P. Darke, B. Pollok, 2002, Journal of biomolecular screening.

Protein expression plasmids produced rapidly: streamlining cloning protocols and robotic handling.

Lawrence C Kuo, Michael Lenard, L. Kuo, 2005, Assay and drug development technologies.

Potent HIV Protease Inhibitors: The Development of Tetrahydrofuranylglycines as Novel P2‐Ligands and Pyrazine. Amides as P3‐Ligands.

Arun K. Ghosh, P. Anderson, P. Darke, 1993 .